VEGFA and neoplasm: Paradoxically, prolonged treatment with bevacizumab often results in tumor hypoxia that adversely induces VEGF expression, leading to increased tumor neovascularization and vessel leakiness and, thus, resulting in a shift of the hypoxic TME to a predominantly infiltrative phenotype [97].